Skip to main content

Table 1 Baseline characteristics

From: Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

  Total
n = 362
Hepatotoxicity
n = 8
No hepatotoxicity
n = 354
p*
Age, median (IQR) 38.5 (33.7–45.8) 39.6 (32.7–40.7) 38.5 (33.8–45.9) 0.479
Female, n (%) 133 (36.7) 6 (75.0) 127 (35.9) 0.055
Naïve patients, n (%) 58 (16.0) 1 (12.5) 57 (16.1) 0.783
Risk group, n (%)
 Eterosexual 181 (50.0) 4 (50.0) 177 (50.0) 0.213
 MSM 83 (22.9) 0 (0.0) 83 (23.5)
 IVDUs 84 (23.2) 4 (50.0) 80 (22.6)
 Others 14 (3.9) 0 (0.0) 14 (3.9)
Caucasian, n (%) 330 (91.1) 7 (87.5) 323 (91.2) 0.527
BMI, median (IQR) 22.4 (20.5–24.5) 19.9 (18.3–22.0) 22.6 (20.6–24.5) 0.017
AIDS, n (%) 63 (17.4) 1 (12.5) 62 (17.5) 0.999
CD4+/mL, median (IQR) 436 (306–593) 555 (479–611) 433 (300–592) 0.157
HIV-RNA log10 cp/mL,median (IQR) 1.75 (0.00–4.09) 0.00 (0.00–2.16) 1.79 (0.00–4.10) 0.229
HCV coinfection, n (%) 131 (31.2) 6 (75.5) 107 (30.2) 0.013
HBV coinfection, n (%) 21 (5.8) 1 (12.5) 20 (5.65) 0.383
AST U/L, median (IQR) 26 (20–38) 58 (29–92) 26 (20–37) 0.041
ALT U/L, median (IQR) 28 (18–50) 82 (37–122) 27 (18–49) 0.047
ARV backbone, n (%)
 ABC 32 (8.8) 1 (12.5) 31 (8.8) 0.311
 AZT/DDI/D4T 223 (61.6) 7 (87.5) 216 (61.0)
 TDF 86 (23.7) 0 (0.0) 86 (24.3)
 Others 21 (5.8) 0 (0.0) 21 (5.9)
  1. Abbreviations: n number, yrs. years, IQR Inter Quartile Range, MSM Man how have sex with man, IVDUs Intra venous drug users, BMI Body Mass Index, cps copies, ABC abacavir, TDF tenofovir diproxil fumarate. *p-values are for χ2 or Fisher’s exact test and Mann-Whitney test